NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catabasis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.51 -0.44 (-6.33 %) (As of 01/24/2020 02:30 AM ET) Add Compare Today's Range$6.40Now: $6.51▼$7.0850-Day Range$5.20MA: $6.01▼$7.0052-Week Range$4.02Now: $6.51▼$9.76Volume138,900 shsAverage Volume135,593 shsMarket Capitalization$76.80 millionP/E RatioN/ADividend YieldN/ABeta1.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CATB Previous Symbol CUSIPN/A CIK1454789 Webhttp://www.catabasis.com/ Phone617-349-1971Debt Debt-to-Equity RatioN/A Current Ratio7.68 Quick Ratio7.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales153.60 Cash FlowN/A Price / Cash FlowN/A Book Value$4.89 per share Price / Book1.33Profitability EPS (Most Recent Fiscal Year)($5.12) Net Income$-25,870,000.00 Net MarginsN/A Return on Equity-61.87% Return on Assets-55.35%Miscellaneous Employees24 Outstanding Shares11,797,000Market Cap$76.80 million Next Earnings Date3/12/2020 (Estimated) OptionableNot Optionable Receive CATB News and Ratings via Email Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CATB Rates by TradingView Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions What is Catabasis Pharmaceuticals' stock symbol? Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB." When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work? Catabasis Pharmaceuticals shares reverse split before market open on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Catabasis Pharmaceuticals' earnings last quarter? Catabasis Pharmaceuticals Inc (NASDAQ:CATB) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.07. View Catabasis Pharmaceuticals' Earnings History. When is Catabasis Pharmaceuticals' next earnings date? Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Catabasis Pharmaceuticals. What price target have analysts set for CATB? 1 Wall Street analysts have issued 1 year price targets for Catabasis Pharmaceuticals' stock. Their forecasts range from $18.00 to $60.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $39.00 in the next year. This suggests a possible upside of 499.1% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals. What is the consensus analysts' recommendation for Catabasis Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals. Has Catabasis Pharmaceuticals been receiving favorable news coverage? Press coverage about CATB stock has trended extremely negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Catabasis Pharmaceuticals. Who are some of Catabasis Pharmaceuticals' key competitors? Some companies that are related to Catabasis Pharmaceuticals include Galera Therapeutics (GRTX), BioXcel Therapeutics (BTAI), Avadel Pharmaceuticals (AVDL), Albireo Pharma (ALBO), MediciNova (MNOV), Advanz Pharma (CXRXF), Neptune Wellness Solutions (NEPT), Geron (GERN), IVERIC bio (ISEE), Kamada (KMDA), Hookipa Pharma (HOOK), Wave Life Sciences (WVE), VBI Vaccines (VBIV), BIOFRONTERA AG/ADR (BFRA) and Sol Gel Technologies (SLGL). What other stocks do shareholders of Catabasis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catabasis Pharmaceuticals investors own include G-III Apparel Group (GIII), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Inovio Pharmaceuticals (INO), Lexicon Pharmaceuticals (LXRX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD) and Aurinia Pharmaceuticals (AUPH). Who are Catabasis Pharmaceuticals' key executives? Catabasis Pharmaceuticals' management team includes the folowing people: Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)Mr. Noah Clauser, VP of Fin. & ControllerMs. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54) When did Catabasis Pharmaceuticals IPO? (CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers. How do I buy shares of Catabasis Pharmaceuticals? Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Catabasis Pharmaceuticals' stock price today? One share of CATB stock can currently be purchased for approximately $6.51. How big of a company is Catabasis Pharmaceuticals? Catabasis Pharmaceuticals has a market capitalization of $76.80 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-25,870,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Catabasis Pharmaceuticals employs 24 workers across the globe.View Additional Information About Catabasis Pharmaceuticals. What is Catabasis Pharmaceuticals' official website? The official website for Catabasis Pharmaceuticals is http://www.catabasis.com/. How can I contact Catabasis Pharmaceuticals? Catabasis Pharmaceuticals' mailing address is 100 High Street Floor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected] MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 462 (Vote Outperform)Underperform Votes: 337 (Vote Underperform)Total Votes: 799MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: What are no-load funds?
